Evergreen Wealth Solutions LLC Sells 167 Shares of Stryker Co. (NYSE:SYK)

Evergreen Wealth Solutions LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 9.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,654 shares of the medical technology company’s stock after selling 167 shares during the period. Evergreen Wealth Solutions LLC’s holdings in Stryker were worth $596,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in SYK. Vanguard Group Inc. increased its holdings in shares of Stryker by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company’s stock valued at $11,773,213,000 after acquiring an additional 252,188 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Stryker by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company’s stock valued at $4,000,056,000 after purchasing an additional 54,693 shares in the last quarter. FMR LLC raised its holdings in Stryker by 10.0% in the fourth quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after buying an additional 727,850 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Stryker by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company’s stock worth $2,539,033,000 after buying an additional 168,436 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $1,710,744,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 1.2 %

Shares of NYSE:SYK opened at $370.92 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a market cap of $141.58 billion, a PE ratio of 47.80, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The stock has a 50 day moving average of $367.06 and a 200 day moving average of $373.49.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm posted $3.46 earnings per share. As a group, equities research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Analysts Set New Price Targets

SYK has been the subject of a number of recent analyst reports. Barclays boosted their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. BTIG Research set a $403.00 price objective on Stryker and gave the company a “buy” rating in a research report on Monday, April 14th. Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $423.53.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.